The mechanism of imipramine in enuresis nocturna
- 1 February 1979
- journal article
- clinical trial
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 6 (1) , 31-35
- https://doi.org/10.1111/j.1440-1681.1979.tb00004.x
Abstract
1. To evaluate the mechanism of action of imipramine in enuresis nocturna, we compared the effects of imipramine with those of scopolamine butylbromide in fourteen children suffering from this condition. A double-blind, cross-over design was used. 2. Imipramine, 10--20 mg, was superior to scopolamine butylbromide (10--20 mg), in eleven of the fourteen subjects (P less than 0.01), and the latter drug was no better than the placebo. 3. As scopolamine butylbromide does not cross the blood-brain barrier, it is concluded that peripheral antimuscarinic effects are not important in the beneficial effects of imipramine in enuresis nocturna. 4. The therapeutic effects of imipramine in depression frequently take 3 to 4 weeks to develop. Such a delay was not seen in our enuretic patients. Thus the mechanism of the drug in the two conditions is probably different.Keywords
This publication has 5 references indexed in Scilit:
- The intestinal absorption of scopolamine-n-butylbromide (Buscopan®) from isolated loops in conscious ratsEuropean Journal of Pharmacology, 1969
- Causes of enuresis.BMJ, 1969
- Effects of hyoscine butylbromide on gut motilityClinical Pharmacology & Therapeutics, 1968
- Sleep Disorders: Disorders of Arousal?Science, 1968
- DRUG TREATMENT OF ENURESIS: CONTROLLED TRIALS WITH PROPANTHELINE, AMPHETAMINE, AND PITUITARY SNUFFThe Lancet, 1956